Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...
Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor ...
NECTIN4 RNA expression and clinical outcomes with first-line (1L) platinum-based chemotherapy (PBC) and avelumab 1L maintenance in locally advanced or metastatic urothelial carcinoma (la/mUC): ...
The Scottish Medicines Consortium has approved a new first-line combination therapy for restricted use in adults with unresectable or metastatic urothelial cancer.
As of the April 20, 2026, data cut-off, 82 patients had been treated, and 72 had completed primary response evaluation. Dr.
Adjuvant pembrolizumab more than doubled disease-free survival (DFS) after radical surgery in patients with high-risk muscle-invasive urothelial cancer, according to new findings from the phase 3 ...
A urine tumor DNA test shows promise for noninvasive detection of bladder cancer and upper tract urothelial carcinoma, which may reduce the burden of cystoscopy. A multitarget urine tumor DNA test ...
Circulating tumor DNA (ctDNA) is an emerging technology that is rapidly transforming the management of patients with cancer -- not only in hematologic malignancies, but increasingly also in solid ...
Early on-treatment weight loss was not associated with progression-free survival or time to discontinuation of enfortumab vedotin. Early weight loss after the start of first-line treatment with ...
They further applied two-sample Mendelian randomization (TSMR) analysis to examine genetic associations between prostate cancer and ten common secondary primary malignancies (SPMs). The study not only ...
Junshi Biosciences receives approval of toripalimab NDA from NMPA for first-line treatment of HER2 expressing urothelial carcinoma: Shanghai Saturday, May 23, 2026, 17:00 Hrs [IST ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results